TY  - CONF

T1  - Weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps1106

PY  - 2015/05/20

AU  - Yardley DA

AU  - Cortes J

AU  - Coleman RE

AU  - Conte PF

AU  - Brufsky A

AU  - O'Shaughnessy J

AU  - Wright GLS

AU  - Eakle JF

AU  - Wilks S

AU  - Shtivelband M

AU  - Young RR et al

ED  - 

DO  - DOI: 10.1200/jco.2015.33.15_suppl.tps1106

PB  - American Society of Clinical Oncology (ASCO)

VL  - 33

IS  - 15_suppl

SP  - TPS1106

EP  - TPS1106

Y2  - 2025/10/10

ER  -